Naltrexone depot formulations for opioid and alcohol dependence: A systematic review

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 629-636

  Lobmaier, Philipp P ^a,b   Kunøe, Nikolaj ^a,b   Gossop, Michael ^b,c   Waal, Helge ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alcoholism; Naltrexone; Opioid dependence; Systematic review

Indexed keywords

NALTREXONE; ONEIL IMPLANT; PLACEBO; PRODETOXON; UNCLASSIFIED DRUG; WEDGEWOOD IMPLANT;

ALCOHOLISM; ALLERGIC REACTION; APPLICATION SITE INFECTION; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; COGNITIVE DEFECT; DRUG FORMULATION; DRUG IMPLANT; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; MUSCLE TWITCH; NAUSEA; OPIATE ADDICTION; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

ALCOHOLISM; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82355169152     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00194.x     Document Type: Review

References (107)

1. Koob GF, LeMoal M. Addiction and the brain antireward system. Annu Rev Psychol 2008;59:29-53.
2. Robinson TE, Berridge KC. The incentive sensitization theory of addiction: Some current issues. Philos Trans R Soc Lond B Biol Sci 2008;363:3137-3146.
3. Nestler EJ. Transcriptional mechanisms of addiction: Role of DeltaFosB. Philos Trans R Soc Lond B Biol Sci 2008;363:3245-3255.
4. Martin WR, Gorodetzky CW, McClane TK. An experimental study in the treatment of narcotic addicts with cyclazocine. Clin Pharmacol Ther 1966;7:455-465.
5. Cone EJ, Gorodetzky CW, Yeh SY. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos 1974;2:506-512.
6. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988;29:1207-1211.
7. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-328.
8. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35:192-213.
9. Resnick RB, Volavka J, Freedman AM, Thomas M. Studies of EN-1639A (naltrexone): A new narcotic antagonist. Am J Psychiatry 1974;131:646-650.
10. Volavka J, Resnick RB, Kestenbaum RS, Freedman AM. Short-term effects of naltrexone in 155 heroin ex-addicts. Biol Psychiatry 1976;11:679-685.
11. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 2006;189:37-46.
12. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci 1980;26:679-688.
13. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-880.
14. Jayaram-Lindstrom N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008;33:1856-1863.
15. Jayaram-Lindstrom N, Wennberg P, Hurd YL, Franck J. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 2004;24:665-669.
16. Widdowson PS, Holman RB. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J Neurochem 1992;59:157-163.
17. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychological Review 1987;94:469-492.
18. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 2002;160:19-29.
19. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006;1: doi:.
20. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-593.
21. Waal H, Kornor H. Abstinence-oriented therapies for opiate addicts. Current Opinion in Psychiatry 2004;17:169-174.
22. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001;58:755-761.
23. Willette RE. The development of sustained action preparations of narcotic antagonists. NIDA Res Monogr 1978;19:333-339.
24. Chiang CN, Hollister LE, Gillespie HK, Foltz RL. Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend 1985;16:1-8.
25. Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;2: doi:.
26. Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004;28:1051-1059.
27. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA 2005;293:1617-1625.
28. Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM. Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry 2008;69:190-195.
29. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007;27:507-512.
30. Lapham S, Forman R, Alexander M, Illeperuma A, Bohn MJ. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J Subst Abuse Treat 2009;36:1-6.
31. Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res 2009;33:350-356.
32. Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: Results from a German multicenter study. J Clin Psychopharmacol 2002;22:592-598.
33. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008;65:135-144.
34. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003:28:1546-1552.
35. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210-218.
36. Kunoe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: Randomised controlled trial. Br J Psychiatry 2009;194:541-546.
37. Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 2009;66:1108-1115.
38. Carreno JE, Alvarez CE, San Narciso GL, Bascarán MT, Díaz M, Bobes J. Maintenance treatment with depot opioid antagonists in subcutaneous implants: An alternative in the treatment of opioid dependence. Addict Biol 2003;8:429-438.
39. Colquhoun R, Tan DY, Hull S. A comparison of oral and implant naltrexone outcomes at 12 months. J Opioid Manag 2005;1:249-256.
40. Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: A pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003;8:211-217.
41. Grusser SM, Thalemann CN, Platz W, Golz J, Partecke G. A new approach to preventing relapse in opiate addicts: A psychometric evaluation. Biol Psychol 2006;71:231-235.
42. Gölz J, Partecke G. Katamnestische Entwicklung Opiatabhängiger nach Naltrexoninduziertem Entzug unter Narkose, naltrexongestützter Rückfallprophylaxe und ambulanter psychosozialer Nachsorge. Suchttherapie 2000;1:166-172.
43. Hulse GK, O'Neil G, Hatton M, Paech MJ. Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesth Intensive Care 2003;31:196-201.
44. Hulse GK, Tait RJ. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users. Addict Biol 2003;8:337-342.
45. Waal H, Christophersen AS, Frogopsahl G, Olsen LH, Morland J. Naltrexone implants: A pilot project. Tidsskr Nor Laegeforen 2003;123:1660-1661.
46. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007; 2: doi:.
47. Reece AS. Chronic ulcers caused by injection of substances: Healing aided by naltrexone. Arch Dermatol 2009;145:375-377.
48. Waal H, Frogopsahl G, Olsen L, Christophersen AS, Morland J. Naltrexone implants: Duration, tolerability and clinical usefulness. A pilot study. Eur Addict Res 2006;12:138-144.
49. Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005;79:351-357.
50. Ngo HT, Tait RJ, rnold-Reed DE, Hulse GK. Mental health outcomes following naltrexone implant treatment for heroin-dependence. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:605-612.
51. Ngo HT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Arch Gen Psychiatry 2008;65:457-465.
52. Tait RJ, Hulse GK. Hospital morbidity associated with the natural history of heroin use. J Opioid Manag 2008;4:321-327.
53. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson RC. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addict Biol 2004;9:67-72.
54. Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008;35:116-124.
55. Reece AS. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. J Subst Abuse Treat 2009;37:256-265.
56. Ravndal E, Amundsen EJ. Mortality among drug users after discharge from inpatient treatment: An 8-year prospective study. Drug Alcohol Depend; 2010;108:65-69.
57. Oliver P, Horspool M, Keen J. Fatal opiate overdose following regimen changes in naltrexone treatment. Addiction 2005;100:560-561.
58. Yoburn BC, Sierra V, Lutfy K. Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation. Brain Res 1990;529:143-148.
59. Yoburn BC, Sierra V, Lutfy K. Chronic opioid antagonist treatment: Assessment of receptor upregulation. Eur J Pharmacol 1989;170:193-200.
60. Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Australia 2007;186:152-153.
61. Hamilton RJ, Olmedo RE, Shah S, et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002;9:63-68.
62. Lintzeris N, Lee S, Scopelliti L, Mabbutt J, Haber PS. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Med J Australia 2008;188:441-444.
63. Kruptisky EM, Burakov AM, Tsoy MV, et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction 2007;102:1164-1165.
64. Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008;103:1399-1401.
65. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases. Addict Biol 2002;7:321-323.
66. Galloway GP, Koch M, Cello R, Smith DE. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: An open-label trial. BMC Psychiatry 2005;5: doi:.
67. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004;28:1356-1361.
68. Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 2005;45:1259-1267.
69. Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcohol Clin Exp Res 1998;22:1074-1079.
70. Dunbar JL, Turncliff RZ, Hayes SC, Farrell CB. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 2007;68:862-870.
71. Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006;30:480-490.
72. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 2002;159:351-360.
73. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: Comparing two naltrexone implants. Addict Biol 2004;9:59-65.
74. Ngo HT, rnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:23-28.
75. Olsen L, Christophersen AS, Frogopsahl G, Waal H, Morland J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Brit J Clin Pharmacol 2004;58:219-222.
76. Ramenskaya GV, Shikh EV, Arzamastsev AP, Kukes VG. Molecular-biological problems of drug design and mechanism of drug action: Pharmacokinetic study of the new domestic hypodermic form of naltrexone: Prodetoxon depot tablets. Pharmaceutical Chemistry Journal 2005;1:1-3.
77. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973;28:784-791.
78. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: Analysis of data from two clinical trials. Psychopharmacology 2001;154:397-402.
79. He S-X, Yu L-C, Wang D-M, Hu S, Jia S-W. Cue-elicited event-related potential evaluation of long-term sustained release naltrexone treatment for opioid dependence. [Chinese]. J Clin Rehab Tissue Eng Res 2008;12:1027-1030.
80. He S-X, Yu L-C, Chen Q, Wang D-M, Hu S, Jia S-W. Effect of long-term sustained release naltrexone on semantic recognition of opioid addicts. J Clin Rehab Tissue Eng Res 2009;13:1573-1576.
81. Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997;45:131-134.
82. Ritter AJ. Naltrexone in the treatment of heroin dependence: Relationship with depression and risk of overdose. Aust N Z J Psychiatry 2002;36:224-228.
83. Miotto K, McCann M, Basch J, Rawson R, Ling W. Naltrexone and dysphoria: Fact or myth? Am J Addiction 2002;11:151-160.
84. Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR. Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci 2006;31:38-45.
85. Hulse GK, Stalenberg V, McCallum D, Smit W, O'Neil G, Morris N, Tait RJ. Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. J Control Release 2005;108:43-55.
86. Hulse GK, Low VH, Stalenberg V, et al. Biodegradability of naltrexone-poly(DL) lactide implants in vivo assessed under ultrasound in humans. Addict Biol 2008;13:364-372.
87. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007;4:24-34.
88. NIAAA. Alcoholic liver disease. Alcohol Alert 2005;64:1-6.
89. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008;93:141-147.
90. NIH. Managment of Hepatitis C. NIH Consensus Conference Statement 2002. Available from: [Accessed 2 September 2010].
91. Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res 2008;32:498-504.
92. Brewer C, Wong VS. Naltrexone: Report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol 2004;9:81-87.
93. O'Brien B, Cody C. Analgesia and sedation in the presence of a naltrexone implant: A novel pharmacological challenge. Eur J Emerg Med 2006;13:315-316.
94. Hulse GK, O'Neill G. A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user. Aust N Z J Obstet Gynaecol 2002;42:93-94.
95. Hulse GK, Arnold-Reed DE, O'Neil G, Hansson RC. Naltrexone implant and blood naltrexone levels over pregnancy. Aust N Z J Obstet Gynaecol 2003;43:386-388.
96. Hulse G, O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002;42:569-573.
97. Hulse GK, O'Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynecol Obstet 2004;85:170-171.
98. Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: Review of human and animal data. Curr Neuropharmacol 2008;6:125-150.
99. Heading CE. Vivitrex (alkermes/cephalon). Curr Opin Investig Drugs 2006;7:81-88.
100. Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opin Pharmacother 2006;7:1065-1073.
101. Martin WR, Sandquist VL. A sustained release depot for narcotic antagonists. Arch Gen Psychiatry 1974;30:31-33.
102. Slawson MH, Chen M, Moody D, Comer SD, Nuwayser ES, Fang WB, Foltz RL. Quantitative analysis of naltrexone and 6beta-naltrexol in human, rat, and rabbit plasma by liquid chromatography-electrospray ionization tandem mass spectrometry with application to the pharmacokinetics of Depotrex in rabbits. J Anal Toxicol 2007;31:453-461.
103. Chaves ME, Chávez MA, Gerez M, Vázquez MT, Maatouk M. Experiencia interdisciplinaria en la problemática del alcoholismo. [Interdisciplinary experience in the problematic one of the alcoholism.] Vis Enferm Actual 2007;3:18-21.
104. Gooberman LL, Bradway DW. Depot naltrexone vs oral naltrexone postdetoxification. J Addict Dis 1998;17:150.
105. Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007;45:111-117.
106. Marlowe DB. Depot naltrexone in lieu of incarceration: A behavioral analysis of coerced treatment for addicted offenders. J Subst Abuse Treat 2006;31:131-139.
107. O'Brien CP. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. Curr Psychiatry Rep 2005;7:327-328.